UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 532

Sortiert nach

A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease

Upsala journal of medical sciences, 2023, Vol.128, p.e10316-10

Lannfelt, Lars

2023

Link zum Volltext

Verfügbarkeit prüfen

The Amyloid-β Pathway in Alzheimer's Disease

Molecular psychiatry, 2021-10, Vol.26 (10), p.5481-5503

2021

Link zum Volltext

Verfügbarkeit prüfen

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease

Neurotherapeutics, 2023-01, Vol.20 (1), p.195-206

2023

Link zum Volltext

Verfügbarkeit prüfen

Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers

Acta neuropathologica, 2018-07, Vol.136 (1), p.41-56

2018

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Alzheimer's research & therapy, 2021-04, Vol.13 (1), p.80-80, Article 80

2021

Link zum Volltext

Verfügbarkeit prüfen

Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease

Nature communications, 2016-02, Vol.7 (1), p.10759-10759, Article 10759

2016

Link zum Volltext

Verfügbarkeit prüfen

Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor

Theranostics, 2017, Vol.7 (2), p.308-318

2017

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal changes in the frequency of mosaic chromosome Y loss in peripheral blood cells of aging men varies profoundly between individuals

European journal of human genetics : EJHG, 2020-03, Vol.28 (3), p.349-357

2020

Link zum Volltext

Verfügbarkeit prüfen

Serial propagation of distinct strains of Aβ prions from Alzheimer’s disease patients

Proceedings of the National Academy of Sciences - PNAS, 2014-07, Vol.111 (28), p.10323-10328

2014

Link zum Volltext

Verfügbarkeit prüfen

Mosaic loss of chromosome Y in leukocytes matters

Nature genetics, 2019-01, Vol.51 (1), p.4-7

2019

Link zum Volltext

Verfügbarkeit prüfen

Vascular risk factors and dementia: 40-year follow-up of a population-based cohort

Dementia and geriatric cognitive disorders, 2011-01, Vol.31 (6), p.460

2011

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease

PloS one, 2016-03, Vol.11 (3), p.e0150672-e0150672

2016

Link zum Volltext

Verfügbarkeit prüfen

The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death

Journal of neuroinflammation, 2018-03, Vol.15 (1), p.98-98, Article 98

2018

Link zum Volltext

Verfügbarkeit prüfen

Microglial Heparan Sulfate Proteoglycans Facilitate the Cluster-of-Differentiation 14 (CD14)/Toll-like Receptor 4 (TLR4)-Dependent Inflammatory Response

The Journal of biological chemistry, 2015-06, Vol.290 (24), p.14904-14914

2015

Link zum Volltext

Verfügbarkeit prüfen

A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils – a new concept for neuroimaging

NeuroImage (Orlando, Fla.), 2017-03, Vol.148, p.55-63

2017

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice

Neurobiology of disease, 2014-09, Vol.69, p.134-143

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

Lancet neurology, 2008, Vol.7 (9), p.779-786

2008

Link zum Volltext

Verfügbarkeit prüfen

Stabilization of neurotoxic Alzheimer amyloid-β oligomers by protein engineering

Proceedings of the National Academy of Sciences - PNAS, 2010-08, Vol.107 (35), p.15595-15600

2010

Link zum Volltext

Verfügbarkeit prüfen

Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation

The Journal of neuroscience, 2012-08, Vol.32 (34), p.11750-11762

2012

Link zum Volltext

Verfügbarkeit prüfen

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease

Neurobiology of disease, 2021-12, Vol.161, p.105543-105543, Article 105543

2021

Link zum Volltext

Verfügbarkeit prüfen

CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer’s Disease

Molecular therapy. Nucleic acids, 2018-06, Vol.11 (C), p.429-440

2018

Link zum Volltext

Verfügbarkeit prüfen

Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes

Journal of neuroinflammation, 2017-12, Vol.14 (1), p.241-241, Article 241

2017

Link zum Volltext

Verfügbarkeit prüfen

Loss of astrocyte polarization in the tg-ArcSwe mouse model of Alzheimer's disease

Journal of Alzheimer's disease, 2011-01, Vol.27 (4), p.711

2011

Link zum Volltext

Verfügbarkeit prüfen

Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimer's disease and frontotemporal dementia

BMC genomics, 2022-02, Vol.23 (1), p.99-99, Article 99

2022

Link zum Volltext

Verfügbarkeit prüfen

Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation

PloS one, 2012-02, Vol.7 (2), p.e32014

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 532

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(510)
Mit Volltextzugriff
(473)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease

The Amyloid-β Pathway in Alzheimer's Disease

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease

Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease

Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor

Longitudinal changes in the frequency of mosaic chromosome Y loss in peripheral blood cells of aging men varies profoundly between individuals

Serial propagation of distinct strains of Aβ prions from Alzheimer’s disease patients

Mosaic loss of chromosome Y in leukocytes matters

Vascular risk factors and dementia: 40-year follow-up of a population-based cohort

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease

The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death

Microglial Heparan Sulfate Proteoglycans Facilitate the Cluster-of-Differentiation 14 (CD14)/Toll-like Receptor 4 (TLR4)-Dependent Inflammatory Response

A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils – a new concept for neuroimaging

Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

Stabilization of neurotoxic Alzheimer amyloid-β oligomers by protein engineering

Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease

CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer’s Disease

Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes

Loss of astrocyte polarization in the tg-ArcSwe mouse model of Alzheimer's disease

Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimer's disease and frontotemporal dementia

Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation

Suchergebnisse filtern